Insider · CIK 0001711184
Jennifer Buell
Files at PTIX (Protagenic Therapeutics, Inc.\new), AGEN (AGENUS INC), INKT (MiNK Therapeutics, Inc.). First filing -, latest -.
In brief
Jennifer Buell files SEC Form 4 as chair, director and CEO at PTIX (Protagenic Therapeutics, Inc.\new), and also at AGEN (AGENUS INC), INKT (MiNK Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jennifer Buell has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 13, 2026 | INKT MiNK Therapeutics, Inc. | 6,938 0.14% of outstanding | $73k | Oct 12, 2026 | none |
Transactions
Every row this insider has filed, 25 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | AGEN AGENUS INC | AGrant or award Stock Optionderivative | +200,000 | $0.00 | $0 | 200,000 | Aug 7, 2026 |
| Apr 24, 2026 | AGEN AGENUS INC | AGrant or award Stock Optionderivative | +300,000 | $0.00 | $0 | 300,000 | Apr 28, 2026 |
| Apr 24, 2026 | AGEN AGENUS INC | AGrant or award Stock Optionderivative | +5,000 | $0.00 | $0 | 5,000 | Apr 28, 2026 |
| Jan 2, 2026 | INKT MiNK Therapeutics, Inc. | FTax withholding Common Stock | -10,024 | $11.12 | $111k | 57,942 | Jan 14, 2026 |
| Jan 2, 2026 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +31,474 | $11.12 | $350k | 67,966 | Jan 6, 2026 |
| Jan 2, 2026 | INKT MiNK Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 6, 2026 |
| Sep 9, 2025 | INKT MiNK Therapeutics, Inc. | FTax withholding Common Stock | -5,351 | $15.36 | $82k | 36,492 | Oct 3, 2025 |
| Sep 9, 2025 | INKT MiNK Therapeutics, Inc. | AGrant or award Common Stock | +18,229 | $15.36 | $280k | 41,913 | Sep 11, 2025 |
| Sep 9, 2025 | INKT MiNK Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Sep 11, 2025 |
| May 2, 2025 | AGEN AGENUS INC | AGrant or award Common Stock | +581 | $3.11 | $1,807 | 19,738 | May 6, 2025 |
| Apr 18, 2025 | AGEN AGENUS INC | AGrant or award Common Stock | +869 | $2.08 | $1,808 | 19,157 | May 5, 2025 |
| Apr 4, 2025 | AGEN AGENUS INC | AGrant or award Common Stock | +1,159 | $1.56 | $1,808 | 18,288 | Apr 10, 2025 |
| Mar 21, 2025 | AGEN AGENUS INC | AGrant or award Common Stock | +1,123 | $1.61 | $1,808 | 17,129 | Mar 27, 2025 |
| Mar 7, 2025 | AGEN AGENUS INC | AGrant or award Common Stock | +409 | $2.35 | $961 | 15,646 | Mar 24, 2025 |
| Feb 21, 2025 | AGEN AGENUS INC | AGrant or award Common Stock | +545 | $3.32 | $1,809 | 15,237 | Mar 11, 2025 |
| Feb 21, 2025 | AGEN AGENUS INC | AGrant or award Common Stock | +626 | $3.32 | $2,078 | 15,318 | Mar 5, 2025 |
| Feb 7, 2025 | AGEN AGENUS INC | AGrant or award Common Stock | +516 | $3.50 | $1,806 | 14,692 | Feb 18, 2025 |
| Jan 24, 2025 | AGEN AGENUS INC | FTax withholding Common Stock | -270 | $3.57 | $964 | 14,176 | Feb 4, 2025 |
| Jan 24, 2025 | AGEN AGENUS INC | AGrant or award Common Stock | +776 | $3.57 | $2,770 | 14,446 | Jan 28, 2025 |
| Nov 14, 2024 | AGEN AGENUS INC | AGrant or award Stock Optionderivative | +300,000 | $0.00 | $0 | 300,000 | Nov 18, 2024 |
| Mar 25, 2024 | PTIX Protagenic Therapeutics, Inc.\new | AGrant or award PTIX Common stock Optionsderivative | +75,000 | $1.74 | $131k | 75,000 | Mar 29, 2024 |
| Jan 16, 2024 | INKT MiNK Therapeutics, Inc. | AGrant or award Stock Optionderivative | +500,000 | $0.00 | $0 | 500,000 | Jan 18, 2024 |
| Jan 16, 2024 | INKT MiNK Therapeutics, Inc. | AGrant or award Stock Optionderivative | +660,919 | $0.00 | $0 | 660,919 | Jan 18, 2024 |
| Oct 11, 2023 | INKT MiNK Therapeutics, Inc. | JOther Common Stock | -695,750 | - | - | 232,165 | Oct 13, 2023 |
| Oct 11, 2023 | INKT MiNK Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | -695,750 | $0.00 | $0 | 0 | Oct 13, 2023 |
Questions about Jennifer Buell
Answered from the filings on this page, as of the latest one.
Is Jennifer Buell buying or selling?
Jennifer Buell has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jennifer Buell's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jennifer Buell has 0.
Where does Jennifer Buell file Form 4?
Jennifer Buell has filed Form 4 at PTIX (Protagenic Therapeutics, Inc.\new); AGEN (AGENUS INC) as See Remarks; INKT (MiNK Therapeutics, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.